Active substance
Results for the substance haemophilus influenzae type b vaccine
3 results
About this active substance
The Haemophilus influenzae type B (Hib) vaccine is used to prevent infections caused by this bacterium, which can include meningitis, pneumonia, epiglottitis, and septicemia. The vaccine contains purified capsular polysaccharides from Haemophilus influenzae type B, conjugated to a carrier protein to stimulate a stronger immune response, especially in infants and young children.
The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for infants and young children. It is included in national immunization programs in many countries due to its effectiveness in reducing the incidence of severe diseases caused by Hib.
Common side effects include pain at the injection site, mild fever, and irritability. In rare cases, severe allergic reactions may occur.
The Haemophilus influenzae type B vaccine is an essential measure for protecting children's health and reducing mortality associated with severe infections caused by this bacterium.
The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for infants and young children. It is included in national immunization programs in many countries due to its effectiveness in reducing the incidence of severe diseases caused by Hib.
Common side effects include pain at the injection site, mild fever, and irritability. In rare cases, severe allergic reactions may occur.
The Haemophilus influenzae type B vaccine is an essential measure for protecting children's health and reducing mortality associated with severe infections caused by this bacterium.